The thread running beneath all of this is the accelerating divergence between formal regulatory channels and the living ecosystem that has grown beyond them. Federal legislation will not move past committee markup in 2026 — the structural conditions are not present. The FDA's internal capacity problems, documented in reporting on the agency's reviewer bandwidth, compound an already delayed MDMA NDA process by a conservative estimate of nine months beyond any announced internal timeline. And yet: veteran-led retreat networks are operational, processing real participants at scale, with projections above 5,000 veterans in informal settings by year's end regardless of what any agency communicates. The highest trajectory available from here is not a single federal gate swinging open — it is a parallel architecture maturing in parallel, with state-level legislation advancing in at least four jurisdictions and providing the regulatory scaffolding that makes eventual federal integration possible rather than chaotic. States are not a consolation prize. They are the laboratory that produces the safety data, the integration protocols, and the political evidence base that federal action will eventually require.
The people inside this story are not abstractions. They are veterans who have already cycled through three or four VA treatment pathways and found nothing that touched the root of what happened to them. They are families watching someone they love function at 40 percent of who they used to be. They are clinicians who have seen the data and are trying to figure out how to serve patients inside a regulatory gap that was not of anyone's making. What is genuinely possible for them right now — not in 2028, not when the NDA resolves, but now — is access to monitored, structured, high-integrity settings that the emerging state frameworks and the best informal networks are already attempting to provide. The cardiac safety literature is not a door closing. It is a set of inclusion criteria forming in real time: who gets screened, how, by whom. That is a solvable problem, and the people who need this most deserve to have it solved with urgency.
Every authentic ceremony is a reclamation — of the body, the breath, the forgotten self. OOTW exists to hold space for that reclamation as the science arrives to name it.
What is forming beneath the surface is always closer than it appears.
72%
Psilocybin research will spawn three competing theories about extinction without relapse
Recent studies show psilocybin can help people quit cocaine by actually changing how the brain processes memory and reward — specifically, it breaks the link between cues and craving while leaving extinction memory intact. This is a weird dissociation that doesn't match current theory. The prediction says scientists will propose at least three different mechanistic explanations for this in peer-reviewed papers within a year. This matters because whoever figures it out right could design better addiction treatments.
→ Scientists will probably publish at least three different competing theories to explain how psilocybin breaks cocaine addiction without relapse, within the next year.
Resolves: 2027-05-11 · Global
RESEARCH
the precise call ▾
The extinction-without-relapse dissociation observed in psilocybin-cocaine studies will generate at least 3 competing mechanistic hypotheses in peer-reviewed literature within 12 months.. Novel dissociations between behavioral extinction and relapse prevention reliably attract competing mechanistic frameworks in addiction neuroscience. The 5-HT2A, neuroplasticity/BDNF, and memory reconsolidation literatures are each primed to claim this finding. Twelve months is sufficient for commen
70%
US states will pass four new psychedelic therapy laws while Congress stays frozen
Colorado and Oregon already have legal psychedelic therapy programs running. Minnesota, Massachusetts, California, Vermont and others are actively writing new bills right now. The prediction says at least four more states will pass laws legalizing or decriminalizing psychedelic-assisted therapy by November 2026, while Congress (the federal government) does nothing. This matters because it creates a patchwork of legal access across the country while the FDA and DEA remain unchanged.
→ At least four more US states will legalize psychedelic therapy by November 2026, but Congress won't pass federal legislation.
Resolves: 2026-11-07 · USA
LEGISLATION
the precise call ▾
At least 4 new U.S. state bills legalizing or decriminalizing psychedelic therapy will pass by 2026-11-07, while no federal psychedelic therapy legislation advances past committee.. State legislative momentum is real and documented (Colorado, Oregon already operational; Minnesota, Massachusetts, California, Vermont active in 2025-2026 sessions). Four bills passing by November 2026 is achievable given current pipeline. Federal inaction is overdetermined by partisan environment,
55%
Veterans will access psychedelic retreats outside the US by 5,000 by late 2026
Groups like Heroic Hearts already run informal psychedelic retreats for military veterans in countries where these substances are legal or tolerated. The prediction says 5,000 veterans total will have used these retreats by the end of 2026. This matters because veterans struggle with PTSD and trauma, and some find relief through these retreats — but they happen in legal gray zones with no oversight.
→ Thousands of veterans are already using informal international psychedelic retreats, but nobody can verify exactly how many because these operations don't report to anyone.
Resolves: 2026-12-31 · USA
CULTURE
the precise call ▾
Veteran-led psychedelic retreat networks will serve over 5,000 veterans in informal settings by end of 2026.. Existing networks (e.g., Heroic Hearts, VETS) are operational and growing. Current trajectory suggests several thousand veterans are already being served annually in informal/international settings. 5,000 cumulative by year-end is plausible but the number is hard to verify independently since these
52%
FDA will formally warn about ibogaine heart rhythm dangers by February 2027
Ibogaine is a powerful plant medicine used to treat addiction, but it can disrupt your heart's electrical system and cause dangerous arrhythmias (irregular heartbeats). The FDA (the US drug regulator) publishes formal safety warnings when enough bad cases pile up. This prediction says they'll do that for ibogaine by early 2027. If they do, it will make any legal access to ibogaine much harder and signal serious risk.
→ The FDA will probably issue an official warning about ibogaine's heart dangers within the next year, which will make it much harder to access legally.
Resolves: 2027-02-11 · USA
REGULATORY
the precise call ▾
FDA will issue a formal safety communication specifically on ibogaine cardiac risks by 2027-02-11.. FDA has issued safety communications on far thinner adverse-event clustering than what is now accumulating around ibogaine QT prolongation. However, the current political environment (DOGE-era FDA staffing cuts, reduced proactive communications) meaningfully reduces the probability that FDA acts pro
28%
FDA or DEA will restrict ibogaine access before it expands in the US
This is a shorter deadline version of the previous prediction — it asks whether regulators will formally constrain ibogaine before the end of summer 2026 (only three months away). The logic is the same: cardiac risks are piling up, but a formal warning this fast is unlikely unless something bad happens suddenly. Most federal agencies move slower than this.
→ Don't expect a formal regulator move on ibogaine in the next three months unless something goes very wrong.
Resolves: 2026-08-09 · USA
REGULATORY
the precise call ▾
Ibogaine will face a formal FDA or DEA safety communication within 12 months (by 2026-08-09) that materially constrains any U.S. access expansion before 2028.. This prediction has a resolve date of 2026-08-09, only ~3 months from today (2026-05-11). Within that compressed window, a formal FDA or DEA safety communication specifically on ibogaine is unlikely absent a high-profile sentinel event. DEA safety communications are rare instruments. FDA proactive c